FOXC1 Activates Smoothened-Independent Hedgehog Signaling in Basal-like Breast Cancer | Zendy

Bingchen Han | Zendy; Ying Qu | Zendy; Yanli Jin | Zendy; Yi Yu | Zendy; Nan Deng | Zendy; Kolja Wawrowsky | Zendy; Xiao Zhang | Zendy; Na Li | Zendy; Shikha Bose | Zendy; Qiang Wang | Zendy; Sugunadevi Sakkiah | Zendy; Ravinder Abrol | Zendy; Tor Jensen | Zendy; Benjamin P. Berman | Zendy; Hisashi Tanaka | Zendy; Jeffrey Johnson | Zendy; Bowen Gao | Zendy; Jijun Hao | Zendy; Zhenqiu Liu | Zendy; Ralph Buttyan | Zendy; Partha Ray | Zendy; MienChie Hung | Zendy; Armando E. Giuliano | Zendy; Xiaojiang Cui | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

FOXC1 Activates Smoothened-Independent Hedgehog Signaling in Basal-like Breast Cancer

Author(s) -

Bingchen Han,

Ying Qu,

Yanli Jin,

Yi Yu,

Nan Deng,

Kolja Wawrowsky,

Xiao Zhang,

Na Li,

Shikha Bose,

Qiang Wang,

Sugunadevi Sakkiah,

Ravinder Abrol,

Tor Jensen,

Benjamin P. Berman,

Hisashi Tanaka,

Jeffrey Johnson,

Bowen Gao,

Jijun Hao,

Zhenqiu Liu,

Ralph Buttyan,

Partha Ray,

MienChie Hung,

Armando E. Giuliano,

Xiaojiang Cui

Publication year - 2015

Publication title -

cell reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.264

H-Index - 154

eISSN - 2639-1856

pISSN - 2211-1247

DOI - 10.1016/j.celrep.2015.09.063

Subject(s) - smoothened , hedgehog signaling pathway , hedgehog , basal (medicine) , breast cancer , biology , cancer research , medicine , microbiology and biotechnology , endocrinology , signal transduction , cancer , insulin

The mesoderm- and epithelial-mesenchymal transition-associated transcription factor FOXC1 is specifically overexpressed in basal-like breast cancer (BLBC), but its biochemical function is not understood. Here, we demonstrate that FOXC1 controls cancer stem cell (CSC) properties enriched in BLBC cells via activation of Smoothened (SMO)-independent Hedgehog (Hh) signaling. This non-canonical activation of Hh is specifically mediated by Gli2. Furthermore, we show that the N-terminal domain of FOXC1 (aa 1-68) binds directly to an internal region (aa 898-1168) of Gli2, enhancing the DNA-binding and transcription-activating capacity of Gli2. FOXC1 expression correlates with that of Gli2 and its targets in human breast cancers. Moreover, FOXC1 overexpression reduces sensitivity to anti-Hedgehog (Hh) inhibitors in BLBC cells and xenograft tumors. Together, these findings reveal FOXC1-mediated non-canonical Hh signaling that determines the BLBC stem-like phenotype and anti-Hh sensitivity, supporting inhibition of FOXC1 pathways as potential approaches for improving BLBC treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research